Choosing Among Emerging Subsequent-Line Cancer Therapies - What Oncologists Weigh

The conversation shifted to hematologic malignancies as Dr. Karr described how quickly cell therapy has moved from experimental to standard: CAR T-cell therapy, approved for roughly a decade, is now available for both lymphoma and multiple myeloma, and bispecific antibodies have entered leukemia consolidation regimens — with both modalities creeping from later-line, academic-only use toward the second line. That set up the episode's central question: once a new therapy shows striking results at a major conference, how do clinicians decide if it's actually right for the patient in front of them?

Dr. Karr's answer was blunt — trial populations and real patients don't always match, and impressive effect sizes can still leave meaningful uncertainty about individual applicability. Dr. Kalantri pushed further, noting that statistical significance and clinical significance aren't the same thing, especially when choosing between two competing second-line agents. Dr. Luo answered with a detailed case study: tarlatamab, a DLL3-targeted bispecific T-cell engager for small cell lung cancer, a disease she described as having offered little beyond chemotherapy until now. The pivotal trial excluded patients with active CNS metastases, a common site of spread for this cancer, yet showed an overall survival plateau near 40%.

She explained how she bridges that gap in practice — leaning on poster sessions and real-world and company-sponsored CNS-outcomes data to extend the drug's use beyond the strict trial population, while tarlatamab is now also being studied in the first-line setting.